ANZUP is the Australian and New Zealand Urogenital and Prostate Cancer Trials Group funded by Cancer Australia to develop and conduct cancer research in Urogenital and Prostate Cancers. The group fosters collaboration between researchers by aiming to minimise the effect of prostate and other urogenital cancers on the community in terms of survival, incidence and quality of life, through research and education and by providing patients and carers with support and will conduct and promote cooperative clinical trials and psychosocial research in prostate and other Urogenital cancers.

The object of ANZUP is to develop, foster and promote prostate and other urogenital cancer research by:

• Filling a niche in Australia and New Zealand in answering clinical questions that are currently not addressed by industry-sponsored or other clinical trials
• Finding ways to create strong links with Cancer Australia and/or other peak bodies aiming to explore and initiate trials in under-researched areas.
• Providing access to clinical trials for all appropriate Australian and New Zealand patients
• Increasing involvement of and collaboration with various professional disciplines in clinical and preclinical research
• Providing opportunities for clinical research
• Building systems to simplify and streamline clinical research of the highest quality
• Identifying strategies for inclusion of functional imaging studies in ANZUP trials
• Promoting systematic collection of tissue and data on trial participants and in general genitourinary oncology clinical practice
• Addressing specific health and medical issues of culturally and linguistically diverse groups and Aboriginal and Torres Strait Islanders by identifying if there is a need to facilitate better clinical and laboratory research in these populations and to develop protocols in such areas
• Providing training opportunities for the next generation of clinical researchers through access to clinical and scientific for basic research and clinical trials For information on current trials read our newsletter.